4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of Moderate Buy from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month […]

Related Keywords

Canada ,David Kirn ,Cantor Fitzgerald ,Goldman Sachs Group ,Nasdaq ,International Assets Investment Management ,D Molecular Therapeutics Company Profile ,Lazard Asset Management ,Us Bancorp ,D Molecular Therapeutics Inc ,Royal Bank ,Molecular Therapeutics ,Get Free Report ,Marketbeat Ratings ,Global Investors Lp Viking ,Asset Management ,Assets Investment Management ,Molecular Therapeutics Stock Down ,Molecular Therapeutics Company ,Get Free ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Ratings ,Consensus ,